Office of the Secretary; Notice of Meeting, 106548-106549 [2024-31064]
Download as PDF
<![CDATA[
106548
Federal Register / Vol. 89, No. 249 / Monday, December 30, 2024 / Notices
Because kidney and liver transplants are
no longer subject to the Research
Criteria, NIH plans to retain these
outcomes only where applicable (e.g.,
for deceased donor heart-living donor
kidney transplants, deceased donor
heart-living donor liver transplants, and
for other organs subject to the Research
Criteria).
Transplant Recipients: NIH has added
several additional data elements and
outcome measures to those included for
transplant recipients in the 2015
Research Criteria. NIH has added the
following outcome measures: type of
rejection (antibody mediated versus
cellular rejection), chronic allograft
vasculopathy (heart), chronic lung
allograft dysfunction (lung), hospital
infections, estimated glomerular
filtration rate (heart and lung), HIV
superinfection, graft failure (heart and
lung), re-transplantation, and
simultaneous multiple organ
transplants.
While not included as a requirement
of the Research Criteria, NIH has
included the following recommendation
regarding patient management:
NIH recommends that transplant
programs and healthcare providers
follow current and updated practice
management guidelines. For specific
guidance, transplant programs and
healthcare providers should consult
vaccination guidance (https://
www.cdc.gov/acip-recs/hcp/vaccinespecific/) and expert
guidance for the management of patients
with HIV pre-, during-, and posttransplant summarized in:
Transplantation in people with HIV
(https://clinicalinfo.hiv.gov/en/
guidelines/hiv-clinical-guidelines-adultand-adolescent-arv/whats-new).
ddrumheller on DSK120RN23PROD with NOTICES1
References
1. Department of Health and Human Services
(DHHS). Human Immunodeficiency
Virus (HIV) Organ Policy Equity (HOPE)
Act Safeguards and Research Criteria for
Transplantation of Organs Infected With
HIV. 80 FR 34912. June 18, 2015.
2. Doberne J.W., et al. (2021). Heart
transplantation survival outcomes of HIV
positive and negative recipients. Annals
of Thoracic Surgery, 111:1465–71.
3. Durand C., et al. (2024). Safety of kidney
transplantation from donors with HIV
infection. N Engl J Med, 391:1390–401.
4. HIV Organ Policy Equity (HOPE) Act of
2013. Public Law 113–51.
5. Kern, R., Seethamraju, H., Blanc, P., Sinha,
N., Loebe, M., Golden, J., et al. (2014).
Lung Transplantation in HIV
Seropositive Patients. Chest, 145(3
Suppl), 642A.
6. Koval C., et al. (2018). Heart and lung
transplantation outcomes in HIV-positive
recipients.
7. Koval, C.E., Farr, M., Krisl, J., Haidar, G.,
VerDate Sep<11>2014
23:58 Dec 27, 2024
Jkt 265001
Pereira, M.R., Shrestha, N., Malinis,
M.F., Mueller, N.J., Hannan, M.M.,
Grossi, P., & Huprikar, S. (2019). Heart or
lung transplant outcomes in HIVinfected recipients. The Journal of heart
and lung transplantation: the official
publication of the International Society
for Heart Transplantation, 38(12), 1296–
1305. https://doi.org/10.1016/
j.healun.2019.09.011.
8. Madan S., et al, (2019). Outcomes of heart
transplantation in patients with human
immunodeficiency virus. Am J
Transplant. 19:1529–35.
9. Rouzaud C., et al., (2022). Lung
transplantation in HIV-positive patients:
a European retrospective cohort study.
Eur Respir J. 60(1):2200189.
10. Storm, K., & Durand, C.M. (2024).
Overcoming barriers and stigma: new
frontiers in solid organ transplantation
for people with HIV. Clinical
microbiology reviews, 37(1), e0011122.
https://doi.org/10.1128/cmr.00111-22.
11. Wairimu, F., Ward, N.C., Liu, Y., &
Dwivedi, G. (2021). Cardiac
Transplantation in HIV-Positive Patients:
A Narrative Review. Journal of acquired
immune deficiency syndromes (1999),
87(2), 763–768. https://doi.org/10.1097/
QAI.0000000000002647.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications
Address: National Institutes of Health,
National Institute of General Medical
Sciences, Natcher Building, 45 Center
Drive, Bethesda, Maryland 20892.
Meeting Format: Virtual Meeting.
Contact Person: Manas
Chattopadhyay, Ph.D., Scientific Review
Officer, Office of Scientific Review,
National Institute of General Medical
Sciences, National Institutes of Health,
45 Center Drive, Room 3AN12N,
Bethesda, Maryland 20892, 301–827–
5320, manasc@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: December 19, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–30873 Filed 12–27–24; 8:45 am]
BILLING CODE 4140–01–P
Dated: December 20, 2024.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2024–31265 Filed 12–27–24; 8:45 am]
Office of the Secretary; Notice of
Meeting
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National
Institute of General Medical Sciences
Special Emphasis Panel Review of
Centers of Biomedical Research
Excellence (COBRE) Phase IIITranslational Centers (P30)
Applications
Date: March 18–19, 2025
PO 00000
Frm 00143
Fmt 4703
Sfmt 4703
National Institutes of Health
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting of Interagency
Autism Coordinating Committee.
The meeting will be virtually held
and is open to public viewing. The
connection information and how to
access the meeting will be available on
the IACC website https://iacc.hhs.gov/
meetings/iacc-meetings/2025/summaryof-advances/january14/. Advanced
registration is recommended.
Individuals wishing to participate
virtually that need special assistance or
other reasonable accommodations
should submit a request to the Contact
Person listed on this notice at least
seven (7) business days prior to the
meeting.
The purpose of the IACC meeting is
to discuss the committee’s nominations
of articles for the 2024 IACC Summary
of Advances in Autism Research report.
The final report will summarize the top
20 advances in autism biomedical and
services research, as selected by the
IACC.
Name of Committee: Interagency Autism
Coordinating Committee 2024 IACC
Summary of Advances in Autism Research.
Date: January 14, 2025.
Time: 2:00 p.m. to 4:00 p.m.
E:\FR\FM\30DEN1.SGM
30DEN1
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 249 / Monday, December 30, 2024 / Notices
Agenda: To discuss the committee’s
nominations of articles for the 2024 IACC
Summary of Advances in Autism Research
report.
Address: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Meeting Format: Virtual Meeting.
Cost: The meeting is free and open to the
public.
Registration: A registration web link will
be posted on the IACC website
(www.iacc.hhs.gov) prior to the meeting. Preregistration is recommended.
Contact Person: Ms. Rebecca Martin, Office
of National Autism Coordination, National
Institute of Mental Health, NIH, Phone: 301–
435–0886, Email: IACCPublicInquiries@
mail.nih.gov.
Technical issues: If you experience any
technical problems with the zoom webcast,
please email IACCPublicInquiries@
mail.nih.gov.
Disability Accommodations: All IACC Full
Committee Meetings provide Closed
Captioning through the Zoom platform.
Individuals whose full participation in the
meeting will require special accommodations
(e.g., sign language or interpreting services,
etc.) must submit a request to the Contact
Person listed on the notice at least seven (7)
business days prior to the meeting. Such
requests should include a detailed
description of the accommodation needed
and a way for the IACC to contact the
requester if more information is needed to fill
the request. Special requests should be made
at least seven (7) business days prior to the
meeting; last-minute requests may be made
but may not be possible to accommodate.
Meeting schedule subject to change.
More Information: Information about the
IACC is available on the website: https://
www.iacc.hhs.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person. In the
interest of security, NIH has procedures at
https://www.nih.gov/about-nih/visitorinformation/campus-access-security for
entrance into on-campus and off-campus
facilities. All visitor vehicles, including
taxicabs, hotel, and airport shuttles will be
inspected before being allowed on campus.
Visitors attending a meeting on campus or at
an off-campus federal facility will be asked
to show one form of identification (for
example, a government-issued photo ID,
driver’s license, or passport) and to state the
purpose of their visit.
Dated: December 20, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–31064 Filed 12–27–24; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
23:58 Dec 27, 2024
Jkt 265001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Fogarty HIV Research Training Program for
Low- and Middle-Income Country
Institutions.
Date: January 23, 2025.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Emily Foley, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 402–3016, emily.foley@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: December 20, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–31149 Filed 12–27–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
PO 00000
Frm 00144
Fmt 4703
Sfmt 4703
106549
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Clinical Trials in Neurology
(III).
Date: January 17, 2025.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Address: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Meeting Format: Virtual Meeting.
Contact Person: Shanta Rajaram, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH/DHHS, NSC, 6001 Executive
Boulevard, Rockville, MD 20852, 301–435–
6033, rajarams@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: December 20, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–31195 Filed 12–27–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary &
Integrative Health; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Integrative Health
E:\FR\FM\30DEN1.SGM
30DEN1
]]>Agencies
[Federal Register Volume 89, Number 249 (Monday, December 30, 2024)]
[Notices]
[Pages 106548-106549]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-31064]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Secretary; Notice of Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting of Interagency
Autism Coordinating Committee.
The meeting will be virtually held and is open to public viewing.
The connection information and how to access the meeting will be
available on the IACC website https://iacc.hhs.gov/meetings/iacc-meetings/2025/summary-of-advances/january14/. Advanced registration is
recommended. Individuals wishing to participate virtually that need
special assistance or other reasonable accommodations should submit a
request to the Contact Person listed on this notice at least seven (7)
business days prior to the meeting.
The purpose of the IACC meeting is to discuss the committee's
nominations of articles for the 2024 IACC Summary of Advances in Autism
Research report. The final report will summarize the top 20 advances in
autism biomedical and services research, as selected by the IACC.
Name of Committee: Interagency Autism Coordinating Committee
2024 IACC Summary of Advances in Autism Research.
Date: January 14, 2025.
Time: 2:00 p.m. to 4:00 p.m.
[[Page 106549]]
Agenda: To discuss the committee's nominations of articles for
the 2024 IACC Summary of Advances in Autism Research report.
Address: National Institutes of Health, Neuroscience Center,
6001 Executive Boulevard, Rockville, MD 20852.
Meeting Format: Virtual Meeting.
Cost: The meeting is free and open to the public.
Registration: A registration web link will be posted on the IACC
website (www.iacc.hhs.gov) prior to the meeting. Pre-registration is
recommended.
Contact Person: Ms. Rebecca Martin, Office of National Autism
Coordination, National Institute of Mental Health, NIH, Phone: 301-
435-0886, Email: [email protected].
Technical issues: If you experience any technical problems with
the zoom webcast, please email [email protected].
Disability Accommodations: All IACC Full Committee Meetings
provide Closed Captioning through the Zoom platform. Individuals
whose full participation in the meeting will require special
accommodations (e.g., sign language or interpreting services, etc.)
must submit a request to the Contact Person listed on the notice at
least seven (7) business days prior to the meeting. Such requests
should include a detailed description of the accommodation needed
and a way for the IACC to contact the requester if more information
is needed to fill the request. Special requests should be made at
least seven (7) business days prior to the meeting; last-minute
requests may be made but may not be possible to accommodate. Meeting
schedule subject to change.
More Information: Information about the IACC is available on the
website: https://www.iacc.hhs.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person. In the interest of security,
NIH has procedures at https://www.nih.gov/about-nih/visitor-information/campus-access-security for entrance into on-campus and
off-campus facilities. All visitor vehicles, including taxicabs,
hotel, and airport shuttles will be inspected before being allowed
on campus. Visitors attending a meeting on campus or at an off-
campus federal facility will be asked to show one form of
identification (for example, a government-issued photo ID, driver's
license, or passport) and to state the purpose of their visit.
Dated: December 20, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee
Policy.
[FR Doc. 2024-31064 Filed 12-27-24; 8:45 am]
BILLING CODE 4140-01-P
